Brain Matters Research, Inc.

Delray Beach, Florida 33445

0 studies enrolling now · 21 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease

Studies at this site

• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease — Stopped early
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab — Completed
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease — Completed
• A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY) — Completed
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy — Completed
• Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• AAB-001 in Patients With Mild to Moderate Alzheimer's Disease — Completed